MK-6837 has been discontinued, the company discloses.
ApexOnco Front Page
Recent articles
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
Three private biotechs enter clinical trials, one targeting KRAS.
The company will start three phase 3 trials of its G12D project this year.
